Biophytis to Present Sarconeos Data at ECCMID
| Field | Detail |
|---|---|
| Company | Biophytis SA |
| Form Type | 6-K |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, conference-presentation, drug-development
TL;DR
Biophytis presenting COVID drug data at big European conference May 15.
AI Summary
Biophytis S.A. announced on May 15, 2025, its participation in the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The company will present data on its drug candidate, Sarconeos (BIO101), for the treatment of COVID-19 and other respiratory diseases.
Why It Matters
This presentation at a major European congress could validate Biophytis's drug candidate, Sarconeos, potentially impacting its future development and market perception.
Risk Assessment
Risk Level: medium — The company is presenting data at a congress, which is a standard disclosure, but the success of the drug candidate is still under development and subject to clinical trial outcomes.
Key Players & Entities
- Biophytis S.A. (company) — Registrant
- Sarconeos (BIO101) (drug_candidate) — Drug being presented
- May 15, 2025 (date) — Date of press release and presentation announcement
- 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) (event) — Conference where data will be presented
- Stanislas Veillet (person) — Contact person for Biophytis S.A.
FAQ
What is the main purpose of this 6-K filing?
The filing announces Biophytis S.A.'s participation in the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and the presentation of data related to its drug candidate, Sarconeos (BIO101).
When was the announcement made?
The announcement was made on May 15, 2025.
What drug candidate is Biophytis presenting data on?
Biophytis is presenting data on its drug candidate Sarconeos (BIO101).
What conditions is Sarconeos (BIO101) being studied for?
Sarconeos (BIO101) is being studied for the treatment of COVID-19 and other respiratory diseases.
Where is Biophytis S.A. headquartered?
Biophytis S.A. is headquartered in Paris, France.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 15, 2025 by Stanislas Veillet regarding Biophytis SA.